Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectivene...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2020-12, Vol.11 (1), p.20 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 20 |
| container_title | Journal of personalized medicine |
| container_volume | 11 |
| creator | Verbenko, Dmitry A Karamova, Arfenya E Artamonova, Olga G Deryabin, Dmitry G Rakitko, Alexander Chernitsov, Alexandr Krasnenko, Anna Elmuratov, Artem Solomka, Victoria S Kubanov, Alexey A |
| description | One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined functions situated on chromosomes 2, 4, and 5, as well as on a single single-nucleotide polymorphism (SNP) on chromosome 23. Pre-selected SNP sets were associated with psoriasis vulgaris analysis, which was used to identify four SNP-associated targeted therapy efficiencies:
(rs1143633),
(
) (rs20541),
(rs2201841), and
(rs1800629) genes. Moreover, we showed that the use of the global polygenic risk score allowed for the prediction of onset psoriasis in Russians. Therefore, these results can serve as a starting point for creating a predictive model of apremilast therapy response in the targeted therapy of patients with psoriasis vulgaris. |
| doi_str_mv | 10.3390/jpm11010020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2474750860</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2474750860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-d6fed7f220a9e4885b535a1f64c24c08c291259018aeefc6bc4e3ee29169c183</originalsourceid><addsrcrecordid>eNpdkc1Lw0AQxRdRVGpP3mXBiyDR_cpmcxGk-AUVi_YoLNvNxG5JsnU3qfjfG7VKdS4zzPx4vOEhdEjJGec5OV8sa0oJJYSRLbTPSJYmQjC5vTHvoWGMC9KXShmTZBftcc4VlzLdR8-XywC1q0xs8WRuQm2sf4HG185G7Br82MXoTIMnpnXQtBG_uXaO730BwbSQtD55ghUEwKYp8HqcRB-ciS4eoJ3SVBGG6z5A0-ur6eg2GT_c3I0ux4kVJG-TQpZQZCVjxOQglEpnKU8NLaWwTFiiLMspS3NClQEorZxZARyg38rcUsUH6OJbdtnNaihs7zOYSi-Dq0141944_ffSuLl-8SudKcYzkfUCJ2uB4F87iK2uXbRQVaYB30XNRCZEnsseH6Djf-jCd6Hpv_uispQoSXrq9JuywccYoPw1Q4n-zE1v5NbTR5v-f9mflPgHDpOURg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2474750860</pqid></control><display><type>article</type><title>Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Verbenko, Dmitry A ; Karamova, Arfenya E ; Artamonova, Olga G ; Deryabin, Dmitry G ; Rakitko, Alexander ; Chernitsov, Alexandr ; Krasnenko, Anna ; Elmuratov, Artem ; Solomka, Victoria S ; Kubanov, Alexey A</creator><creatorcontrib>Verbenko, Dmitry A ; Karamova, Arfenya E ; Artamonova, Olga G ; Deryabin, Dmitry G ; Rakitko, Alexander ; Chernitsov, Alexandr ; Krasnenko, Anna ; Elmuratov, Artem ; Solomka, Victoria S ; Kubanov, Alexey A</creatorcontrib><description>One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined functions situated on chromosomes 2, 4, and 5, as well as on a single single-nucleotide polymorphism (SNP) on chromosome 23. Pre-selected SNP sets were associated with psoriasis vulgaris analysis, which was used to identify four SNP-associated targeted therapy efficiencies:
(rs1143633),
(
) (rs20541),
(rs2201841), and
(rs1800629) genes. Moreover, we showed that the use of the global polygenic risk score allowed for the prediction of onset psoriasis in Russians. Therefore, these results can serve as a starting point for creating a predictive model of apremilast therapy response in the targeted therapy of patients with psoriasis vulgaris.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm11010020</identifier><identifier>PMID: 33383665</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenosine ; Clinical outcomes ; Cytokines ; Deoxyribonucleic acid ; Disease ; DNA ; Drug dosages ; Erythema ; FDA approval ; Genomes ; Health risk assessment ; Interleukin 1 ; Interleukin 13 ; Interleukin 4 ; Pathogenesis ; Patients ; Pharmacogenomics ; Phosphodiesterase ; Phosphodiesterase IV ; Population ; Precision medicine ; Prediction models ; Pregnancy ; Psoriasis ; Psoriasis vulgaris ; Signal transduction ; Single-nucleotide polymorphism ; Skin ; Tumor necrosis factor-α</subject><ispartof>Journal of personalized medicine, 2020-12, Vol.11 (1), p.20</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-d6fed7f220a9e4885b535a1f64c24c08c291259018aeefc6bc4e3ee29169c183</citedby><cites>FETCH-LOGICAL-c409t-d6fed7f220a9e4885b535a1f64c24c08c291259018aeefc6bc4e3ee29169c183</cites><orcidid>0000-0003-0567-7734 ; 0000-0003-3778-4745 ; 0000-0002-1104-7694</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823747/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823747/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33383665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verbenko, Dmitry A</creatorcontrib><creatorcontrib>Karamova, Arfenya E</creatorcontrib><creatorcontrib>Artamonova, Olga G</creatorcontrib><creatorcontrib>Deryabin, Dmitry G</creatorcontrib><creatorcontrib>Rakitko, Alexander</creatorcontrib><creatorcontrib>Chernitsov, Alexandr</creatorcontrib><creatorcontrib>Krasnenko, Anna</creatorcontrib><creatorcontrib>Elmuratov, Artem</creatorcontrib><creatorcontrib>Solomka, Victoria S</creatorcontrib><creatorcontrib>Kubanov, Alexey A</creatorcontrib><title>Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis</title><title>Journal of personalized medicine</title><addtitle>J Pers Med</addtitle><description>One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined functions situated on chromosomes 2, 4, and 5, as well as on a single single-nucleotide polymorphism (SNP) on chromosome 23. Pre-selected SNP sets were associated with psoriasis vulgaris analysis, which was used to identify four SNP-associated targeted therapy efficiencies:
(rs1143633),
(
) (rs20541),
(rs2201841), and
(rs1800629) genes. Moreover, we showed that the use of the global polygenic risk score allowed for the prediction of onset psoriasis in Russians. Therefore, these results can serve as a starting point for creating a predictive model of apremilast therapy response in the targeted therapy of patients with psoriasis vulgaris.</description><subject>Adenosine</subject><subject>Clinical outcomes</subject><subject>Cytokines</subject><subject>Deoxyribonucleic acid</subject><subject>Disease</subject><subject>DNA</subject><subject>Drug dosages</subject><subject>Erythema</subject><subject>FDA approval</subject><subject>Genomes</subject><subject>Health risk assessment</subject><subject>Interleukin 1</subject><subject>Interleukin 13</subject><subject>Interleukin 4</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Pharmacogenomics</subject><subject>Phosphodiesterase</subject><subject>Phosphodiesterase IV</subject><subject>Population</subject><subject>Precision medicine</subject><subject>Prediction models</subject><subject>Pregnancy</subject><subject>Psoriasis</subject><subject>Psoriasis vulgaris</subject><subject>Signal transduction</subject><subject>Single-nucleotide polymorphism</subject><subject>Skin</subject><subject>Tumor necrosis factor-α</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkc1Lw0AQxRdRVGpP3mXBiyDR_cpmcxGk-AUVi_YoLNvNxG5JsnU3qfjfG7VKdS4zzPx4vOEhdEjJGec5OV8sa0oJJYSRLbTPSJYmQjC5vTHvoWGMC9KXShmTZBftcc4VlzLdR8-XywC1q0xs8WRuQm2sf4HG185G7Br82MXoTIMnpnXQtBG_uXaO730BwbSQtD55ghUEwKYp8HqcRB-ciS4eoJ3SVBGG6z5A0-ur6eg2GT_c3I0ux4kVJG-TQpZQZCVjxOQglEpnKU8NLaWwTFiiLMspS3NClQEorZxZARyg38rcUsUH6OJbdtnNaihs7zOYSi-Dq0141944_ffSuLl-8SudKcYzkfUCJ2uB4F87iK2uXbRQVaYB30XNRCZEnsseH6Djf-jCd6Hpv_uispQoSXrq9JuywccYoPw1Q4n-zE1v5NbTR5v-f9mflPgHDpOURg</recordid><startdate>20201229</startdate><enddate>20201229</enddate><creator>Verbenko, Dmitry A</creator><creator>Karamova, Arfenya E</creator><creator>Artamonova, Olga G</creator><creator>Deryabin, Dmitry G</creator><creator>Rakitko, Alexander</creator><creator>Chernitsov, Alexandr</creator><creator>Krasnenko, Anna</creator><creator>Elmuratov, Artem</creator><creator>Solomka, Victoria S</creator><creator>Kubanov, Alexey A</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0567-7734</orcidid><orcidid>https://orcid.org/0000-0003-3778-4745</orcidid><orcidid>https://orcid.org/0000-0002-1104-7694</orcidid></search><sort><creationdate>20201229</creationdate><title>Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis</title><author>Verbenko, Dmitry A ; Karamova, Arfenya E ; Artamonova, Olga G ; Deryabin, Dmitry G ; Rakitko, Alexander ; Chernitsov, Alexandr ; Krasnenko, Anna ; Elmuratov, Artem ; Solomka, Victoria S ; Kubanov, Alexey A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-d6fed7f220a9e4885b535a1f64c24c08c291259018aeefc6bc4e3ee29169c183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenosine</topic><topic>Clinical outcomes</topic><topic>Cytokines</topic><topic>Deoxyribonucleic acid</topic><topic>Disease</topic><topic>DNA</topic><topic>Drug dosages</topic><topic>Erythema</topic><topic>FDA approval</topic><topic>Genomes</topic><topic>Health risk assessment</topic><topic>Interleukin 1</topic><topic>Interleukin 13</topic><topic>Interleukin 4</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Pharmacogenomics</topic><topic>Phosphodiesterase</topic><topic>Phosphodiesterase IV</topic><topic>Population</topic><topic>Precision medicine</topic><topic>Prediction models</topic><topic>Pregnancy</topic><topic>Psoriasis</topic><topic>Psoriasis vulgaris</topic><topic>Signal transduction</topic><topic>Single-nucleotide polymorphism</topic><topic>Skin</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verbenko, Dmitry A</creatorcontrib><creatorcontrib>Karamova, Arfenya E</creatorcontrib><creatorcontrib>Artamonova, Olga G</creatorcontrib><creatorcontrib>Deryabin, Dmitry G</creatorcontrib><creatorcontrib>Rakitko, Alexander</creatorcontrib><creatorcontrib>Chernitsov, Alexandr</creatorcontrib><creatorcontrib>Krasnenko, Anna</creatorcontrib><creatorcontrib>Elmuratov, Artem</creatorcontrib><creatorcontrib>Solomka, Victoria S</creatorcontrib><creatorcontrib>Kubanov, Alexey A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verbenko, Dmitry A</au><au>Karamova, Arfenya E</au><au>Artamonova, Olga G</au><au>Deryabin, Dmitry G</au><au>Rakitko, Alexander</au><au>Chernitsov, Alexandr</au><au>Krasnenko, Anna</au><au>Elmuratov, Artem</au><au>Solomka, Victoria S</au><au>Kubanov, Alexey A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis</atitle><jtitle>Journal of personalized medicine</jtitle><addtitle>J Pers Med</addtitle><date>2020-12-29</date><risdate>2020</risdate><volume>11</volume><issue>1</issue><spage>20</spage><pages>20-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined functions situated on chromosomes 2, 4, and 5, as well as on a single single-nucleotide polymorphism (SNP) on chromosome 23. Pre-selected SNP sets were associated with psoriasis vulgaris analysis, which was used to identify four SNP-associated targeted therapy efficiencies:
(rs1143633),
(
) (rs20541),
(rs2201841), and
(rs1800629) genes. Moreover, we showed that the use of the global polygenic risk score allowed for the prediction of onset psoriasis in Russians. Therefore, these results can serve as a starting point for creating a predictive model of apremilast therapy response in the targeted therapy of patients with psoriasis vulgaris.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33383665</pmid><doi>10.3390/jpm11010020</doi><orcidid>https://orcid.org/0000-0003-0567-7734</orcidid><orcidid>https://orcid.org/0000-0003-3778-4745</orcidid><orcidid>https://orcid.org/0000-0002-1104-7694</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2020-12, Vol.11 (1), p.20 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_proquest_journals_2474750860 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adenosine Clinical outcomes Cytokines Deoxyribonucleic acid Disease DNA Drug dosages Erythema FDA approval Genomes Health risk assessment Interleukin 1 Interleukin 13 Interleukin 4 Pathogenesis Patients Pharmacogenomics Phosphodiesterase Phosphodiesterase IV Population Precision medicine Prediction models Pregnancy Psoriasis Psoriasis vulgaris Signal transduction Single-nucleotide polymorphism Skin Tumor necrosis factor-α |
| title | Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A39%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apremilast%20Pharmacogenomics%20in%20Russian%20Patients%20with%20Moderate-to-Severe%20and%20Severe%20Psoriasis&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Verbenko,%20Dmitry%20A&rft.date=2020-12-29&rft.volume=11&rft.issue=1&rft.spage=20&rft.pages=20-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm11010020&rft_dat=%3Cproquest_pubme%3E2474750860%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2474750860&rft_id=info:pmid/33383665&rfr_iscdi=true |